Skip to main content
. 2020 Dec 2;13:162. doi: 10.1186/s13045-020-00995-y

Fig. 2.

Fig. 2

Positioning of JAK inhibitors in the treatment schema of myelofibrosis. ESA—erythropoiesis-stimulating agent; EMA—erythroid maturation agent; IMiD—immunomodulatory imide drugs; BET—Bromodomain and Extraterminal domain Protein; PI3K—Phosphatidylinositol 3-Kinase; MDM—murine double minute; IDH—isocitrate dehydrogenase